However, validation of these findings is warranted through prospective, multi-center-controlled cohort studies due to constraints related to sample size.<h4>Conclusion</h4>In HER2-negative advanced gastric cancer, a ≥26% increase in LDH following two treatment cycles serves as an independent prognostic risk factor. This evidence concerns the gene ERBB2 and gastric cancer.